We are working to transform the way in which viral therapies for cancer are discovered and developed. Our platform technology enables the identification of best-in-class oncolytic viruses, to unlock the full potential of this therapeutic modality. Oncolytic viruses leverage multiple mechanisms of action including direct virus-mediated lysis and stimulation of anti-tumour immunity.
Direct virus-mediated lysis
Oncolytic viruses have the capability to selectively infect, replicate in, and kill (lyse) cancer cells. Selective viral replication enables the therapy to ‘self-amplify’ and spread throughout the tumour, even in heterogeneous tumour types. Viral lysis is more selective than chemotherapy (which is broadly potent in all rapidly dividing cells), whilst demonstrating broader spectrum efficacy than antibody or CAR-T therapies (with selectivity for markers on the cancer cell surface, which may not be present on all cancer cells).
Stimulation of anti-tumour immunity
On cancer cell lysis, cancer-associated markers (antigens) are released into the tumour environment. This triggers the body’s immune system to detect and clear the tumour cells. When a cancer is excluding immune cells (a common mechanism to hide from the body’s natural defenses), some types of therapy are ineffective. Viruses have the ability to pull immune cells into tumours and synergise with these existing treatments – such as checkpoint inhibitors – when delivered in combination.
Our phenotypic screening Platform integrates three breakthrough technologies to transform the discovery and development of oncolytic viral therapies. We are virus-class agnostic, identifying the best therapeutic candidate for a chosen Target Product Profile. Our focus is on identifying transformative products for patients.
Our clinic-ready viral therapies are:
- optimised for a chosen Target Product Profile;
- efficacious and targeted;
- suitable for intravenous, systemic delivery;
- viable for large-scale, high titre manufacture.
Through both in-house development and strategic partnerships, we are rapidly developing a pipeline of next generation therapeutics targeting a range of key oncology indications.